Login
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc.

avalotx.com

What Do They Do?

Develops antibody treatments for people with immune-mediated inflammatory diseases, including hidradenitis suppurativa.

How Do They Make Money?

Historically, wholesale distributors bought prescription drugs, with sales counted when the product reached them. Avalo does not expect gross product sales until possible commercialization of its pipeline candidates.

FY2025 revenue

Who Are Their Customers?

Avalo sold Millipred in the United States primarily through wholesale distributors.

Do Revenues Turn Into Profits?

No. It lost $78.3M in FY2025.

Operating income, FY2025
−123602% of revenue
▼ −6% (Loss) vs FY2024 (−$68.5M, −15536%)
Net income, FY2025
−132642% of revenue
▼ −123% (Loss) vs FY2024 (−$35.1M, −7966%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +38% (Loss)
vs −$30.6M in Q3 FY2025

Shrinking. Revenue fell 99% in 4 years, from $5.4M in FY2021 to $59K in FY2025, about 68% a year.

Treatment focus The older report centered its pipeline on the LIGHT-signaling network; the latest report describes treatments for immune-mediated inflammatory diseases and identifies abdakibart for hidradenitis suppurativa as its main candidate.

Asthma program The older report said Avalo was developing an antibody for non-eosinophilic asthma; the latest report lists its LIGHT antibody among legacy programs it is not currently pursuing.

Who Do They Compete With?

Competes with Novartis, GenSci, Sunshine Guojian, TavoTek, AbbVie, UCB, Moonlake Immunotherapies, Incyte, Lilly, Merck, Pfizer, Sanofi, and Takeda

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support